

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-42. (Canceled)

43. (Currently Amended) An unformulated dry ~~heparin-like~~ glycosaminoglycan having a mean geometric diameter of 1-500 microns.

44-57. (Canceled)

58. (Currently Amended) A method for delivering a ~~heparin-like~~ glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject the ~~heparin-like~~ glycosaminoglycan of claim 43.

59-115. (Canceled)

116. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-200 microns.

117. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-53 microns.

118. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated ~~dry~~ ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-5 microns.

119. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 5-53 microns.

120. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 53-106 microns.

121. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the ~~heparin-like~~ glycosaminoglycan is a heparin, a ~~heparin~~ heparan sulfate, or a low molecular weight heparin.

122-203. (Canceled)

204. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 10-500 microns.

205. (Canceled)

206. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 10-250 microns.

207. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 10-100 microns.

208. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 100-200 microns.

209. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 100-150 microns.

210. (Canceled)

211. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 20-53 microns.

212. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 53-75 microns.

213. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 75-106 microns.

214-222. (Canceled)

223. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-50 microns.

224. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-20 microns.

225. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-100 microns.

226. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 1-250 microns.

227. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 5-200 microns.

228. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a mean geometric diameter of 5-30 microns.

229. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a tap density of 0.01 - 0.4 g/cm³.

230. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a tap density of greater than 0.4 g/cm³.

231. (Currently Amended) The unformulated dry ~~heparin-like~~ glycosaminoglycan of claim 43, wherein the unformulated dry ~~heparin-like~~ glycosaminoglycan has a tap density of less than 0.4 g/cm³.

232. (Currently Amended) A method for producing a therapeutic effect, comprising, administering to a pulmonary tissue of a subject the ~~heparin-like~~ glycosaminoglycan of claim 43.

233-234. (Canceled)

235. (New) The unformulated dry glycosaminoglycan of claim 43, wherein the glycosaminoglycan is a heparin-like glycosaminoglycan.

236. (New) The method of claim 58, wherein the glycosaminoglycan is a heparin-like glycosaminoglycan.

237. (New) The method of claim 232, wherein the glycosaminoglycan is a heparin-like glycosaminoglycan.

238. (New) The method of claim 232, wherein the therapeutic effect is treatment of a coagulation disorder, a thrombotic disorder, a cardiovascular disease, a vascular condition, atherosclerosis, a respiratory disorder, cancer, an angiogenic disorder, circulatory shock or Alzheimer's disease.